Extracellular ATP: A Feasible Target for Cancer Therapy

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Nov 20

PMID 33212982

Citations 100

Authors

Valentina Vultaggio-Poma

Alba Clara Sarti

Francesco Di Virgilio

Affiliations

Soon will be listed here.

Abstract

Adenosine triphosphate (ATP) is one of the main biochemical components of the tumor microenvironment (TME), where it can promote tumor progression or tumor suppression depending on its concentration and on the specific ecto-nucleotidases and receptors expressed by immune and cancer cells. ATP can be released from cells via both specific and nonspecific pathways. A non-regulated release occurs from dying and damaged cells, whereas active release involves exocytotic granules, plasma membrane-derived microvesicles, specific ATP-binding cassette (ABC) transporters and membrane channels (connexin hemichannels, pannexin 1 (PANX1), calcium homeostasis modulator 1 (CALHM1), volume-regulated anion channels (VRACs) and maxi-anion channels (MACs)). Extracellular ATP acts at P2 purinergic receptors, among which P2X7R is a key mediator of the final ATP-dependent biological effects. Over the years, P2 receptor- or ecto-nucleotidase-targeting for cancer therapy has been proposed and actively investigated, while comparatively fewer studies have explored the suitability of TME ATP as a target. In this review, we briefly summarize the available evidence suggesting that TME ATP has a central role in determining tumor fate and is, therefore, a suitable target for cancer therapy.

Citing Articles

Enhancing immunotherapy with tumour-responsive nanomaterials.

Linderman S, DeRidder L, Sanjurjo L, Foote M, Alonso M, Kirtane A Nat Rev Clin Oncol. 2025; .

PMID: 40050505 DOI: 10.1038/s41571-025-01000-6.

Volume-regulated anion channels conduct ATP in undifferentiated mammary cells and promote tumorigenesis in xenograft nude mouse.

Furuya K, Hirata H, Kobayashi T, Ishiguro H, Sokabe M Front Cell Dev Biol. 2025; 12:1519642.

PMID: 39882260 PMC: 11774906. DOI: 10.3389/fcell.2024.1519642.

Stress-Driven Production of γ-Aminobutyric Acid Using Non-Conventional Yeast Strains JMY140K and JMY075.

Fan T, Chen C, Zeng D, Wang F, Xu Z, Jin M J Fungi (Basel). 2025; 11(1).

PMID: 39852440 PMC: 11766319. DOI: 10.3390/jof11010020.

PKCα regulates the secretion of PDL1-carrying small extracellular vesicles in a p53-dependent manner.

Zhang R, Liao W, Chen X, Wang J, Li J, Chen G Cell Death Dis. 2025; 16(1):19.

PMID: 39809736 PMC: 11733117. DOI: 10.1038/s41419-025-07341-5.

The Role of Adenosine in Overcoming Resistance in Sarcomas.

Cruz-Ramos M, Cabrera-Nieto S, Murguia-Perez M, Fajardo-Espinoza F Int J Mol Sci. 2024; 25(22).

PMID: 39596278 PMC: 11594806. DOI: 10.3390/ijms252212209.

References

Vancraenenbroeck R, Webb M . A Fluorescent, Reagentless Biosensor for ATP, Based on Malonyl-Coenzyme A Synthetase. ACS Chem Biol. 2015; 10(11):2650-7. PMC: 4655421. DOI: 10.1021/acschembio.5b00346. View

Ferrari D, Pizzirani C, Gulinelli S, Callegari G, Chiozzi P, Idzko M . Modulation of P2X7 receptor functions by polymyxin B: crucial role of the hydrophobic tail of the antibiotic molecule. Br J Pharmacol. 2007; 150(4):445-54. PMC: 2189724. DOI: 10.1038/sj.bjp.0706994. View

Erlinge D, Burnstock G . P2 receptors in cardiovascular regulation and disease. Purinergic Signal. 2008; 4(1):1-20. PMC: 2245998. DOI: 10.1007/s11302-007-9078-7. View

Burnstock G, Di Virgilio F . Purinergic signalling and cancer. Purinergic Signal. 2013; 9(4):491-540. PMC: 3889385. DOI: 10.1007/s11302-013-9372-5. View

Di Virgilio F, Schmalzing G, Markwardt F . The Elusive P2X7 Macropore. Trends Cell Biol. 2018; 28(5):392-404. DOI: 10.1016/j.tcb.2018.01.005. View

Burnstock G, Campbell G, Satchell D, Smythe A . Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. Br J Pharmacol. 1970; 40(4):668-88. PMC: 1702901. DOI: 10.1111/j.1476-5381.1970.tb10646.x. View

Agteresch H, Dagnelie P, Rietveld T, van den Berg J, Danser A, Wilson J . Pharmacokinetics of intravenous ATP in cancer patients. Eur J Clin Pharmacol. 2000; 56(1):49-55. DOI: 10.1007/s002280050719. View

Wang J, Ambrosi C, Qiu F, Jackson D, Sosinsky G, Dahl G . The membrane protein Pannexin1 forms two open-channel conformations depending on the mode of activation. Sci Signal. 2014; 7(335):ra69. PMC: 4243966. DOI: 10.1126/scisignal.2005431. View

Corriden R, Insel P, Junger W . A novel method using fluorescence microscopy for real-time assessment of ATP release from individual cells. Am J Physiol Cell Physiol. 2007; 293(4):C1420-5. DOI: 10.1152/ajpcell.00271.2007. View

10.

Dou L, Chen Y, Cowan P, Chen X . Extracellular ATP signaling and clinical relevance. Clin Immunol. 2017; 188:67-73. DOI: 10.1016/j.clim.2017.12.006. View

11.

Beigi R, Kobatake E, Aizawa M, Dubyak G . Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. Am J Physiol. 1999; 276(1):C267-78. DOI: 10.1152/ajpcell.1999.276.1.C267. View

12.

Di Virgilio F, Adinolfi E . Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2016; 36(3):293-303. PMC: 5269532. DOI: 10.1038/onc.2016.206. View

13.

Faigle M, Seessle J, Zug S, El Kasmi K, Eltzschig H . ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. PLoS One. 2008; 3(7):e2801. PMC: 2474679. DOI: 10.1371/journal.pone.0002801. View

14.

Pietrocola F, Pol J, Vacchelli E, Rao S, Enot D, Baracco E . Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell. 2016; 30(1):147-160. PMC: 5715805. DOI: 10.1016/j.ccell.2016.05.016. View

15.

Dwyer K, Deaglio S, Gao W, Friedman D, Strom T, Robson S . CD39 and control of cellular immune responses. Purinergic Signal. 2008; 3(1-2):171-80. PMC: 2096766. DOI: 10.1007/s11302-006-9050-y. View

16.

Nakatsuka T, Gu J . P2X purinoceptors and sensory transmission. Pflugers Arch. 2006; 452(5):598-607. DOI: 10.1007/s00424-006-0057-6. View

17.

Matty M, Knudsen D, Walton E, Beerman R, Cronan M, Pyle C . Potentiation of P2RX7 as a host-directed strategy for control of mycobacterial infection. Elife. 2019; 8. PMC: 6351102. DOI: 10.7554/eLife.39123. View

18.

Fabre A, Vantourout P, Champagne E, Terce F, Rolland C, Perret B . Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes. Cell Mol Life Sci. 2006; 63(23):2829-37. PMC: 2020515. DOI: 10.1007/s00018-006-6325-y. View

19.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

20.

Adinolfi E, Callegari M, Ferrari D, Bolognesi C, Minelli M, Wieckowski M . Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. 2005; 16(7):3260-72. PMC: 1165409. DOI: 10.1091/mbc.e04-11-1025. View